Territory Development Sample Clauses
Territory Development. Within the first year after the Effective Date, Distributor shall have commercially launched the Products fully in all its channels in each country in the Territory. For purposes of this Agreement, if an approved sub-distributor has been appointed for the country, a full commercial launch means that the Products are being distributed to at least 70% of the accounts of the sub-distributor. If Distributor has not appointed an approved sub-distributor for the country, a full commercial launch means that the Products are being distributed to at least as many outlets as would equal 70% of the accounts serviced by the largest beverage distributor in that country; provided that at the request of Distributor, made not more than four months after the Effective Date, the Company will consider in good faith alternative definitions for commercial launch in specified countries.
Territory Development. Within the first year after the Effective Date, Distributor shall have commercially launched the Products fully in all its channels in each country in the Territory. For purposes of this Agreement, a full commercial launch means that the Products are being distributed to at least 70% of the accounts of the Distributor in the Territory.
Territory Development. To supply the Products to the Distributor's customers in the Territory.
Territory Development. If the Eisai desires to undertake Territory Development for an Eisai Collaboration Product that is Required Development, New Development or Discretionary Development, then Eisai may propose such Territory Development by submitting to Company and the JDC a written summary of, and proposed protocol for, such Territory Development. The JDC shall consider in good faith, take into account and implement where possible the reasonable comments made by Company with respect to such Territory Development and the JDC shall prepare amendments to the then-current Development Plan and Annual Development Plan Budget in each case for approval by the JSC, subject to Section 3.2(a). Upon JSC approval, Eisai shall undertake such Territory Development.
Territory Development. All Development of the Licensed Products in the Territory will be conducted pursuant to separate written development plans for each distinct indication, each of which will be approved by the JSC (as each such plan is updated from time to time in accordance with this Section 4.2 (Territory Development) and Section 3.2 (Joint Steering Committee), a “Territory Development Plan”), and Kissei will be primarily responsible for all Territory Development activities for the Licensed Products. The initial Territory Development Plan for the Licensed Products is set forth on Schedule 4.2 (Territory Development Plan) attached hereto, and includes Territory-Specific Clinical Trials designed to obtain Regulatory Approval of Licensed Products containing each Licensed Antibody for the treatment of each of active ▇▇▇ and chronic ▇▇▇. Each Territory Development Plan and all updates thereto will contain in reasonable detail (a) [***], (b) [***], and (c) [***]. In addition, at least annually during the Term (or more frequently, as required, upon the occurrence of significant milestone events, such as data readouts or regulatory interactions, or the decision to Develop and obtain regulatory approval for the Licensed Antibodies and Licensed Products), the JSC will review, discuss, and determine whether to approve any updates to each Territory Development Plan. Notwithstanding any provision to the contrary set forth in this Agreement, [***], each Territory Development Plan and all updates thereto must be consistent with a written plan for worldwide development of the Licensed Products as provided to Kissei by Viridian from time to time (the “Global Development Plan”). Upon delivery by Kissei of an Additional Global Clinical Trial Participation Notice in accordance with Section 4.3.1 (Notice of New Global Clinical Trial) for an indication that is not at such time a Territory Development Indication, as further described in Section 4.3.2 (Participation in Additional Global Clinical Trial), the Parties will develop a new Territory Development Plan for such indication and submit such Territory Development Plan to the JSC to review, discuss, and determine whether to approve within the applicable [***] day period. Without limiting the foregoing, within [***] days following ▇▇▇▇▇▇’s receipt from Viridian of each updated Global Development Plan, Kissei will submit to the JSC updated Territory Development Plans for each Territory Development Indication that align with the most recent Globa...
Territory Development